Pulmonary metastasis of breast cancer requires recruitment and expansion of T-regulatory cells (Treg) that promote escape from host protective immune cells. However, it remains unclear precisely how tumors recruit Tregs to support metastatic growth. Here we report the mechanistic involvement of a unique and previously undescribed subset of regulatory B cells. 
Introduction
Cancer escape is an active process that regulates immune responses by employing at least 2 types of suppressive cells, myeloid suppressive cells (MSC) and T-regulatory cells (Treg; ref. [1] [2] [3] . For example, in the mouse mammary adenocarcinoma 4T1 cancer model, which represents a highly aggressive model of human breast carcinoma (4), cancer-produced granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin1b (IL-1b), and TGF-b promote the generation of MSCs to impair antitumor immune responses and promote metastases either through direct action or indirectly by activating Tregs (5) . Tregs are key subsets of CD4 þ T cells that control peripheral tolerance to self-and alloantigens (6) , and the majority of them phenotypically can be identified by the expression of CD25 (IL2Ra) and a fork-head box P3 (FoxP3) gene product (7) . They suppress T-cell responses by acting directly or through the inhibition of antigen-presenting cells (APC; ref. [7] [8] [9] involving cell contact-, FasL/Fas-, and PD1/B7-H1-dependent processes (10-13), or secreted factors such as IL-10, TGF-b, IL-27, and IL-35 (14) (15) (16) (17) . As a result, Tregs are considered to play a key role in the escape of cancer cells from antitumor effector T cells (20) (21) (22) (23) , although the role of other immune cells remains poorly understood. Although a handful of reports indicate that B cells can disable CD4 þ T-cell help for CTL-mediated tumor immunity in mice (18) , or promote epithelial carcinogenesis and castration-resistant prostate cancer (19, 20) , the role or existence of cancer-associated regulatory B cells (Breg) remains unknown. However, suppressive B cells and Bregs were shown to exist and participate in the protective immune responses against autoimmune diseases (21) (22) (23) (24) . For example, T celldependent autoimmunity in mice is associated with the lack of a small subset (1%-2% of B220 þ cells) of IL-10-producing 
CD38
High B cells in humans are linked with protection from murine chronic colitis (26, 27) and systemic lupus erythematosus, respectively (28) . Interestingly, although the suppressive activity of B cells can be IL-10 independent, for example, in protection from experimental autoimmune encephalitis (29) , the majority of them appear to utilize 28) . In fact, lipopolysaccharide (LPS) activation of naïve B cells alone can induce IL-10 production and suppress T-cell responses inducing H-Y antigen tolerance (30) .
Recently, we have reported that lung metastasis of mammary adenocarcinoma 4T1 implanted in the mammary gland of immune competent BALB/c mice requires an active participation of Tregs to inactivate antitumor defenses of natural killer (NK) cells (4) . The process was also associated with the expansion of Tregs that appeared to be induced without involvement of MSCs (4) . Here 
Materials and Methods

Reagents, cells, and mice
The majority of reagents were described in our recent report (3) . In brief, female BALB/c, C57Bl/6, nonobese diabetic severe combined immunodeficient [NOD/SCID (NOD.CB17-Prkdcscid/J; H-2 4T1-PE cells were generated from 4T1 by using TARC-PE38 chemotoxin (3). Splenocytes from FoxP3-GFP mice were a gift from Dr. Rachel Caspi (NEI/NIH) and Dr. Vijay Kochroo (Harvard Medical School). Primary untransformed murine embryonic fibroblasts CD1 and DR4 were used at passages 3 to 6 and were the gift of Dr. Lioudmila Sharova (NIA/NIH).
In vitro tBreg and Treg generation and T-cell suppression assay
Murine splenic B cells were isolated by negative selection using the RoboSep magnetic purification system (StemCell Technologies). For tBreg generation, B cells were incubated with 50% cancer conditioned media (CM) for 2 days in complete RPMI (cRPMI). Control B cells were treated with PBS, or 100 ng/mL B-cell activating factor belonging to the TNF family (BAFF), or 5 mg/mL LPS. Cancer CM was collected from confluent cancer cells, and for some experiments, to generate serum-free CM, cRPMI was replaced and the cells cultured for 72 hours in serum-free media (Life Sciences). Mouse CD3 þ T cells were isolated from naïve mouse spleen using T-cell enrichment columns (R&D Systems). To generate non-Tregs (purity >99.5%), CD4 þ T cells were isolated by mouse T cell CD4 Subset Column Kit and separated from CD25 þ cells using
were used as Tregs. To test the suppressive effects of B cells, B cells were cultured together with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen)-labeled non-Tregs or Tregs (1 Â 10 5 ) in the presence of anti-CD3/CD28-coupled beads and IL-2 (500 U/mL) for 5 days. Decrease in CFSE expression of T cells correlates with the proportion of cells that underwent divisions. B cells were also isolated from spleens of tumor-bearing mice using anti-CD19 antibody (Ab) beads after 3 rounds of depletion of MSCs using anti-Gr1 Ab beads (Miltenyi Biotec). 
In vivo manipulations
Animal care was provided in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 1985) . The experiments were carried out using 4-to 8-week-old female mice in a pathogen-free environment at the National Institute on Aging Animal Facility (Baltimore, MD). To deplete Tregs and tBregs, mice were intraperitoneally (i.p.) injected with Abs to mouse CD25 (500 mg; PC-61, BioXcell) and B220 (400 mg; RA3.3A1, BioXcell) or control IgG at days 3, 10, and 18 posttumor challenge. To restore metastasis, NOD/SCID mice were i.v. injected with 1 Â 10 7 tBregs, generated from naïve BALB/c B cells treated for 2 days with CM-4T1PE, together with equal amounts of BALB/c non-Tregs at days À1, 3, and 7 after tumor challenge. Control NOD/SCID mice were injected with 1 Â 10 7 BALB/c non-Tregs. Congeneic mice were challenged with s.c 4T1.2 tumor cells (in fourth mammary gland with 1 Â 10 4 cells) or 1 Â 10 5 B16 melanoma F10 cells; tumor growth was measured every other day. Mice were culled after 28 days of tumor challenge and lungs were analyzed for metastasis as previously described (3) . Tumor burden in the lungs was quantified by counting nodules.
Results
Lung metastases require the participation of a unique subset of B cells
We recently reported that murine 4T1 breast cancer promotes expansion of Tregs to utilize them in lung metastases (3) . Interestingly, although this expansion can be induced by MSCs, which are also expanded in tumor-bearing mice, MSCs appear not to be involved in the de novo conversion of Tregs (3). The search for other Treg-converting APCs led us to find an enhanced population of CD25-expressing B220 þ CD19 þ B cells in the peripheral blood and secondary lymphoid organs of tumor-bearing mice (Fig. 1A) . Similar cells were also readily generated in naïve mice s.c. injected with CM of 4T1 cells [CM-4T1, and specifically, by their nonmetastatic 4T1 cells, CM-4T1PE (Fig. 1B) and CM-4T1R4 ( Supplementary Fig. S1 )] or in vitro from purified naïve mouse B cells treated with cancer CM (Fig. 1C) . CD25 expression can also be induced in B cells treated with mitogens like LPS (Fig. 1C) . However, unlike LPS, tumor CM-treated B cells only upregulated CD25 without proliferation (Fig. 1C ). It appears that this was the 4T1 cancer CM-associated process, as CM from untransformed murine fibroblasts or murine A20 B-cell lymphoma did not activate Research.
on July 31, 2017. © 2011 American Association for Cancer cancerres.aacrjournals.org Downloaded from tumor-bearing mice were treated with Ab targeting B220 alone (to deplete B cells) or in combination with CD25 (PC61 Ab, routinely used for Treg depletion). Although control Ab-treated mice succumbed to massive lung metastases, both anti-B220 and anti-CD25 Abs, which depleted splenic B220 þ and CD25 þ cells ( Supplementary Fig. S3a ), almost completely abrogated lung metastases (Fig. 1D) . Importantly, treatment with anti-B220 Ab also reversed the enhanced proportion of CD25-expressing B220 Fig. S5 ). Unlike resting B cells, tBregs retained high viability (at least up to 96 hours; Supplementary Fig. S6 ) and expressed constitutively active Stat3 (Fig. 3A) . Fig. 3B ), as they reduced expression of CD62L and upregulated CD69, B7-H1, and CD81 (Fig. 3B ). This does not appear to be an isolated mouse phenomenon, as healthy donor peripheral blood CD19 þ B cells treated with CM from a number of human cancer cells, including ovarian and colon, upregulated CD25 ( Supplementary Fig. S7A ) and suppressed proliferation of human CD3 þ T cells stimulated with anti-CD3/CD28 Abs and IL-2 ( Fig. 3C and D) . As with mice, B cells treated with LPS did not suppress T-cell activity ( Fig. 3C and D) . Thus, human cancers also induce the generation of tBregs. 
or LPS (B-LPS, red line), or PBS (B-PBS, blue line) after staining with Abs to corresponding surface markers (indicated), or isotype-matched control Ab (gray filled area). C, human B cells treated with CM of MDA-MB-231 cells (B-MDA231), but not MCF-7 cells (B-MCF7), or LPS (B-LPS), or PBS (B-PBS), suppress proliferation of T cells. Histograms (B and C) and graphs (D) show % (AE SEM of triplicates) of CD3
þ T cells that diluted CFSC (proliferated) when mixed with B cells at a 1:1 ratio as in Fig. 2A .
D, similarly with B-MDA231, B cells treated with tBregs induce the generation of FoxP3 þ Tregs
Next, to test the mechanism of Breg-mediated suppression, we separated tBregs from T cells by a porous membrane, and found that this disabled the suppressive activity of tBregs (Fig. 4A) . Thus, the process required cell contact to exert T-cell suppression. However, all our attempts to link the suppression with known mechanisms failed. For example, tBregs did not affect viability of T cells and did not utilize common regulatory pathways, such as B7-H1 (Fig. 4B) and Fas (Supplementary Fig. S7B and C) , or soluble cytokines IL-10, IL-27, and IL-35 (the factors abundantly expressed in tBregs; Supplementary Fig. S7D-F) . Finally, the IL-2 competition theory can be also ruled out, as the suppression was not affected by the presence of high doses of IL-2 ( Fig. 4B; Supplementary  Fig. S7D ).
On the other hand, tBregs expressed high levels of CD40, CD80, CD86, and MHC class I and II molecules (Fig. 3B ) and high levels of TGFb (Fig. 4C) , suggesting that tBregs could be promoting Treg conversion. To test this idea, purified non- . 4D ), a key marker of Tregs (7). This is not a result of the expansion of contaminating preexisting Tregs, as their proportion in our non-Treg preparations was below 0.01% (see also Fig. 5A ) and, compared with control B cells, tBregs did not enhance (if not reduced) proliferation of purified
Abs in the presence of high doses of IL-2 (Fig. 4E ). Importantly, highly purified green fluorescent protein-negative (GFP À ) CD4 þ T cells from FoxP3-GFP mice (32) were also induced to express GFP/FoxP3 when only incubated with tBregs, but not control B cells (Fig. 5A ). To confirm that these newly converted FoxP3 þ T cells also acquired regulatory activity, the naïve CD8 þ T cells. Indeed, the tBreg-generated FoxP3 þ T cells, but not with T cells incubated with control B cells, inhibited proliferation of CD8 þ T cells (Fig. 5B) . The process required TGF-b, as the ability to convert Tregs was completely blocked in the presence of ALK5 inhibitor SB431542, a selective inhibitor of the TGF-b type I receptor activity (Fig. 5A and  C) . Moreover, the fact that naive BALB/c mice transferred with tBregs, but not mock-treated B cells, had significantly enhanced numbers of FoxP3 þ Tregs in peripheral blood (and at lesser degrees in spleens, although not statistically significant; Fig. 5D ), suggest that tBregs also promote Treg conversion in vivo as in cancer-bearing mice.
tBreg-induced Tregs promote lung metastasis
Because lung metastasis of 4T1 cancer cells is a Tregdependent process that is also associated with the expansion of Tregs (3), the role of tBregs in lung metastasis (see Fig. 1D and E) is to promote conversion of Tregs. To show this, we utilized T-and B-cell-deficient H-2d-matched NOD/SCID mice that do not support metastasis of 4T1 cancer cells unless adoptively transferred with Tregs (3). Although control mice transferred with either tBregs alone (data not shown) or nonTregs were almost free of lung metastases (Fig. 6A) , the mice that received ex vivo-generated tBregs together with nonTregs from BALB/c mice succumbed to massive lung metastasis (Fig. 6A) , suggesting that the process used tBreg-induced Tregs. Indeed, consistent with our report on the importance of Tregs in lung metastases (3), the transfer of newly in vitro converted Tregs (cultured with tBregs and then depleted of tBregs, >98%; Fig. 5B ), but not normal B cell-treated T cells, also restored the ability of 4T1 cells to metastasize in NOD/ SCID mice (Fig. 6B) . Thus, taken together with the inability of 4T1 cancer cells to metastasize in immune competent BALB/c mice depleted of B220 þ B cells (Fig. 1D) , our data suggest that the role of tBregs in lung metastases is to induce Treg conversion. This is not a 4T1 cancer-associated phenomenon, as B16 melanoma could not efficiently progress in mice that did not have mature B cells (33), unless they were adoptively transferred with congenic tBregs generated by treating them with cancer CM (JHT KO þ tBregs; Fig. 6C ).
Discussion
We previously reported that murine breast cancer induces expansion of Tregs to utilize them in lung metastasis (3) . The search for the cells responsible for this expansion has led us to find a new subset of regulatory B cells, tBregs, which are actively generated from normal B cells in response to the direct effects of cancer-produced factors. tBregs also play an essential role in lung metastases, as they at least induce conversion of metastasis-supporting FoxP3 Fig. S8A ) or the depletion of Tregs in tumor-bearing BALB/c mice ( Supplementary  Fig. S8B ) enhanced or reduced MSC numbers, respectively. Thus, it is tempting to speculate that Tregs and tBregs may cross-talk with MSCs, which can also induce Tregs and supported metastasis (1, 2, 5, 34), by providing or receiving survival benefits to further enhance immune suppression. Although we do not know how cancers induce the generation of tBregs, a subject of a separate study being conducted in the authors' laboratory, this is (to our knowledge) the first report on the existence of tBregs. It remains to be seen whether tBregs may represent a population of B cells shown to have tumor-promoting properties (18) (19) (20) (19, 20) .
Collectively, as summarized in Fig. 6D , our findings indicate that tumor-evoked regulatory B cells are crucial for lung metastasis, acting to convert resting T cells to regulatory T cells that promote immune escape in the target tissue. However, the tBregs by themselves are actively generated from normal B cells in response to cancer cell-produced factors utilizing yet unknown mechanisms, and this appears to be quite a widespread phenomenon, as a number of human cancer lines (breast, ovarian, and colon carcinomas) also induced the generation of tBregs. Thus, the clinical implication of our finding is that, as long as cancer persists, it will induce the generation of tBregs and thereby initiate the chain of suppressive events leading to metastasis. Hence, tBregs need to be controlled to efficiently combat cancers, as in the absence of tBregs, cancer cannot metastasize into the lungs due to a poor Treg conversion. For example, clinically available antibodies such as the pan B-cell antibody, anti-CD20 antibody (rituximab) or the anti-IL-2Ra antibody (daclizumab) could bypass the tBregmediated blockade of the immune response to some cancers.
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